Evaluation of Withania somnifera (L.) Dunal (Ashwagandha) on Physical Performance, Biomarkers of Inflammation, and Muscle Status in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Study
Raut A, Tripathi R, Marathe PA, Uchil DA, Agashe S, Rege N, Vaidya AB
Cureus · 7 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2024-09-08 · Cureus · vol. 16 · número 9 · pág. e68940
- Editorial
- Cureus, Inc.
- Citado
- 5 citas · más que el 89% de estudios similares · 2.5× el promedio de su campo
- Referencias
- 23 trabajos
- Acceso
- Acceso abierto (publicación gratuita) · CC-BY
- Áreas de investigación
- Phytochemicals and Medicinal Plants · Health, Education, and Aging · Phytochemistry Medicinal Plant Applications
- Palabras clave
- Withania somnifera, Medicine, Placebo, Inflammation, Traditional medicine, Double blind, Randomized controlled trial, Pharmacology, Physical therapy, Internal medicine, Pathology, Alternative medicine
7 autores
- Ashwinikumar Anand Raut🇮🇳Kasturba Hospital
- Raakhi Kaliprasad Tripathi🇮🇳King Edward Memorial Hospital and Seth G.S. Medical College
- Padmaja Anil Marathe🇮🇳King Edward Memorial Hospital and Seth G.S. Medical College
- Dinesh Uchil🇮🇳King Edward Memorial Hospital and Seth G.S. Medical College
- Shubhada Agashe🇮🇳Kasturba Hospital
- Nima Rege🇮🇳King Edward Memorial Hospital and Seth G.S. Medical College
- Ashok B. Vaidya🇮🇳Kasturba Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Sarcopenia is associated with chronic inflammation, a sedentary lifestyle, and ageing. However, there exists no drug, which is safe and effective for long-term use. Ashwagandha (Withaniasomnifera (L.) Dunal) has the potential to fill this therapeutic gap based on its efficacy and safety profile; hence, the present study was planned to evaluate its effect on inflammatory biomarkers and muscle status in healthy volunteers.
Methodology
A prospective, double-blind, randomized, placebo-controlled clinical study was conducted to evaluate the effects of Ashwagandha extract in healthy volunteers (February 2021 to May 2022) who received either Ashwagandha extract tablets 250 mg or a placebo twice daily for 60 days. The physical performance on a bicycle ergometer, inflammatory/muscle status biomarkers, body composition, reaction time, hemogram, and organ function tests was assessed at baseline, day 30, and day 60.
Results
In the Ashwagandha group, there was a statistically significant (p2 max showed an increasing trend from V3 to V7, whereas the results of the three inflammatory markers (hs-C-reactive protein (CRP) mg/L; IL-6; TNF-alpha ) and the muscle marker (myostatin) revealed a decreasing trend from V3 to V7 in the Ashwagandha group. Ashwagandha extract was found to be safe in healthy volunteers as evidenced by the clinical profile, laboratory investigations, and reaction time test.
Conclusion
Ashwagandha extract supplementation was safe and effective in enhancing physical performance and strengthening muscle mass and could be a potential candidate for treating sarcopenia.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.